{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:28Z","timestamp":1792714288526,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41591-021-01643-9","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T12:03:23Z","timestamp":1642766603000},"page":"39-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":301,"title":["A guide to immunotherapy for COVID-19"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-4894","authenticated-orcid":false,"given":"Frank L.","family":"van de Veerdonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3577-5629","authenticated-orcid":false,"given":"Lennie","family":"Derde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job J.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joost","family":"Wiersinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P. J.","family":"Vlaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-2538","authenticated-orcid":false,"given":"Manu","family":"Shankar-Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-5079","authenticated-orcid":false,"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek C.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos W. M.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-6052","authenticated-orcid":false,"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"1643_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e6 (2020).","journal-title":"Cell"},{"key":"1643_CR2","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"1643_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446.e14 (2020).","journal-title":"Cell"},{"key":"1643_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03513-9","volume":"25","author":"Y Jouan","year":"2021","unstructured":"Jouan, Y., Baranek, T., Si-Tahar, M., Paget, C. & Guillon, A. Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS. Crit. Care 25, 120 (2021).","journal-title":"Crit. Care"},{"key":"1643_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992\u20131000.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"1643_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","volume":"71","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis. 71, 1937\u20131942 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1643_CR7","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Invest."},{"key":"1643_CR8","doi-asserted-by":"publisher","first-page":"580250","DOI":"10.3389\/fimmu.2020.580250","volume":"11","author":"D Payen","year":"2020","unstructured":"Payen, D. et al. A longitudinal study of immune cells in severe COVID-19 patients. Front. Immunol. 11, 580250 (2020).","journal-title":"Front. Immunol."},{"key":"1643_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40560-020-00453-4","volume":"8","author":"I Huang","year":"2020","unstructured":"Huang, I. & Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J. Intensive Care 8, 1\u201310 (2020).","journal-title":"J. Intensive Care"},{"key":"1643_CR10","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1152\/physrev.00037.2012","volume":"93","author":"KN Iskander","year":"2013","unstructured":"Iskander, K. N. et al. Sepsis: multiple abnormalities, heteroge-neous responses, and evolving understanding. Physiol. Rev. 93, 1247\u20131288 (2013).","journal-title":"Physiol. Rev."},{"key":"1643_CR11","doi-asserted-by":"crossref","unstructured":"Du, R. H. et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2: a prospective cohort study. Eur. Respir. J. 55, 2000524 (2020).","DOI":"10.1183\/13993003.00524-2020"},{"key":"1643_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/infdis\/jiab065","volume":"223","author":"NAF Janssen","year":"2021","unstructured":"Janssen, N. A. F. et al. Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19. J. Infect. Dis. 223, 1322\u20131333 (2021).","journal-title":"J. Infect. Dis."},{"key":"1643_CR13","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","volume":"26","author":"AG Laing","year":"2020","unstructured":"Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623\u20131635 (2020).","journal-title":"Nat. Med."},{"key":"1643_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.immuni.2021.05.002","volume":"54","author":"S Kreutmair","year":"2021","unstructured":"Kreutmair, S. et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity 54, 1578\u20131593.e5 (2021).","journal-title":"Immunity"},{"key":"1643_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21702-6","volume":"12","author":"P Bost","year":"2021","unstructured":"Bost, P. et al. Deciphering the state of immune silence in fatal COVID-19 patients. Nat. Commun. 12, 1\u201315 (2021).","journal-title":"Nat. Commun."},{"key":"1643_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jvsv.2020.08.030","volume":"9","author":"AT Obi","year":"2021","unstructured":"Obi, A. T., Barnes, G. D., Napolitano, L. M., Henke, P. K. & Wakefield, T. W. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. J. Vasc. Surg. Venous Lymphat. Disord. 9, 23\u201335 (2021).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"1643_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"1643_CR18","first-page":"m1295","volume":"368","author":"T Chen","year":"2020","unstructured":"Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. Brit. Med. J. 368, m1295 (2020).","journal-title":"Brit. Med. J."},{"key":"1643_CR19","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMc2010419","volume":"382","author":"P Goyal","year":"2020","unstructured":"Goyal, P. et al. Clinical Characteristics of Covid-19 in New York City. N. Engl. J. Med. 382, 2372\u20132374 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR20","doi-asserted-by":"crossref","unstructured":"Mandal, S. et al. \u2018Long-COVID\u2019: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76, 396\u2013398 (2021).","DOI":"10.1136\/thoraxjnl-2020-215818"},{"key":"1643_CR21","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"130","author":"EM Bloch","year":"2020","unstructured":"Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. 130, 2757\u20132765 (2020).","journal-title":"J. Clin. Invest."},{"key":"1643_CR22","doi-asserted-by":"crossref","unstructured":"Shankar-Hari, M., Spencer, J., Sewell, W. A., Rowan, K. M. & Singer, M. Bench-to-bedside review: Immunoglobulin therapy for sepsis \u2014 biological plausibility from a critical care perspective. Crit. Care 16, 206 (2012).","DOI":"10.1186\/cc10597"},{"key":"1643_CR23","doi-asserted-by":"crossref","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).","DOI":"10.1172\/jci.insight.123158"},{"key":"1643_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"S Bournazos","year":"2020","unstructured":"Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633\u2013643 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1643_CR25","doi-asserted-by":"crossref","unstructured":"Zinsser H., Batchelder A. P. Studies on Mexican typhus fever. I. J. Exp. Med. 51, 847\u2013858 (1930).","DOI":"10.1084\/jem.51.6.847"},{"key":"1643_CR26","doi-asserted-by":"publisher","first-page":"e150646","DOI":"10.1172\/JCI150646","volume":"131","author":"MR O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell, M. R. et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J. Clin. Invest. 131, e150646 (2021).","journal-title":"J. Clin. Invest."},{"key":"1643_CR27","doi-asserted-by":"crossref","unstructured":"Arnold Egloff, S. A. et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J. Clin. Invest. 131, e151788 (2021).","DOI":"10.1172\/JCI151788"},{"key":"1643_CR28","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.16525","volume":"61","author":"JW Senefeld","year":"2021","unstructured":"Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 61, 2503\u20132511 (2021).","journal-title":"Transfusion"},{"key":"1643_CR29","first-page":"1","volume":"7","author":"V Piechotta","year":"2020","unstructured":"Piechotta, V. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst. Rev. 7, 1\u2013293 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1643_CR30","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani, O. et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397, 2049\u20132059 (2021).","journal-title":"Lancet"},{"key":"1643_CR31","unstructured":"Writing Committee for the REMAP-CAP Investigators et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 326, 1690\u20131702 (2021)."},{"key":"1643_CR32","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","volume":"10","author":"A Aiello","year":"2019","unstructured":"Aiello, A. et al. Immunosenescence and Its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front. Immunol. 10, 2247 (2019).","journal-title":"Front. Immunol."},{"key":"1643_CR33","doi-asserted-by":"crossref","unstructured":"Libster, R. et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med. 384, 610\u2013618 (2021).","DOI":"10.1056\/NEJMc2104747"},{"key":"1643_CR34","doi-asserted-by":"crossref","unstructured":"Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA 325, 632\u2013644 (2021).","DOI":"10.1001\/jama.2021.0202"},{"key":"1643_CR35","doi-asserted-by":"publisher","unstructured":"RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to 4 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.06.15.21258542 (2021).","DOI":"10.1101\/2021.06.15.21258542"},{"key":"1643_CR36","doi-asserted-by":"publisher","first-page":"eabc8511","DOI":"10.1126\/science.abc8511","volume":"369","author":"D Mathew","year":"2020","unstructured":"Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020).","journal-title":"Science"},{"key":"1643_CR37","doi-asserted-by":"crossref","unstructured":"Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern. Med. 180, 934\u2013943 (2020).","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"1643_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR39","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus, D. C. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA 324, 1330\u20131341 (2020).","journal-title":"JAMA"},{"key":"1643_CR40","doi-asserted-by":"crossref","unstructured":"Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 324, 1307\u20131316 (2020).","DOI":"10.1001\/jama.2020.17021"},{"key":"1643_CR41","doi-asserted-by":"crossref","unstructured":"Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 324, 1330\u20131341 (2020).","DOI":"10.1001\/jama.2020.17023"},{"key":"1643_CR42","unstructured":"Rochwerg, B. et al. A living WHO guideline on drugs for COVID-19. Brit. Med. J. 370, m3379 (2020)."},{"key":"1643_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353\u2013377 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1643_CR44","doi-asserted-by":"crossref","unstructured":"Jacobs, C. F., Eldering, E. & Kater, A. P. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv. 5, 913\u2013925 (2021).","DOI":"10.1182\/bloodadvances.2020003768"},{"key":"1643_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med. 384, 795\u2013807 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR46","first-page":"1","volume":"19","author":"VC Marconi","year":"2021","unstructured":"Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 19, 1\u201312 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1643_CR47","unstructured":"Aman, J. et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir. Med. 9, 957\u2013968 (2021)."},{"key":"1643_CR48","doi-asserted-by":"crossref","unstructured":"Guimar\u00e3es, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 385, 406\u2013415 (2021).","DOI":"10.1056\/NEJMoa2101643"},{"key":"1643_CR49","unstructured":"Tharaux, P.-L. et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med. 9, 295\u2013304 (2021)."},{"key":"1643_CR50","doi-asserted-by":"publisher","unstructured":"The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.06.18.21259133 (2021).","DOI":"10.1101\/2021.06.18.21259133"},{"key":"1643_CR51","doi-asserted-by":"crossref","unstructured":"Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care 24, 187 (2020).","DOI":"10.1186\/s13054-020-02897-4"},{"key":"1643_CR52","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1681\/ASN.2020060829","volume":"31","author":"TU Azam","year":"2020","unstructured":"Azam, T. U. et al. Soluble urokinase receptor (SuPAR) in COVID-19-related AKI. J. Am. Soc. Nephrol. 31, 2725\u20132735 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1643_CR53","unstructured":"Kyriazopoulou, E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10, e66125 (2021)."},{"key":"1643_CR54","doi-asserted-by":"crossref","unstructured":"Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752\u20131760 (2021).","DOI":"10.1038\/s41591-021-01499-z"},{"key":"1643_CR55","doi-asserted-by":"crossref","unstructured":"Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. JAMA 326, 230\u2013239 (2021).","DOI":"10.1001\/jama.2021.9508"},{"key":"1643_CR56","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645 (2021).","journal-title":"Lancet"},{"key":"1643_CR57","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR58","doi-asserted-by":"crossref","unstructured":"Domingo, P. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. JAMA 326, 499\u2013518 (2021).","DOI":"10.1001\/jama.2021.11330"},{"key":"1643_CR59","doi-asserted-by":"publisher","unstructured":"Patel, J. et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.04.14.21255475 (2021).","DOI":"10.1101\/2021.04.14.21255475"},{"key":"1643_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22781-1","volume":"12","author":"B Diao","year":"2021","unstructured":"Diao, B. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat. Commun. 12, 2506 (2021).","journal-title":"Nat. Commun."},{"key":"1643_CR61","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1016\/S2666-5247(20)30144-0","volume":"1","author":"B Schurink","year":"2020","unstructured":"Schurink, B. et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 1, e290\u2013e299 (2020).","journal-title":"Lancet Microbe"},{"key":"1643_CR62","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","volume":"114","author":"SV Seshan","year":"2009","unstructured":"Seshan, S. V. et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 114, 1675\u20131683 (2009).","journal-title":"Blood"},{"key":"1643_CR63","doi-asserted-by":"crossref","unstructured":"Kambas, K. et al. C5a and TNF-\u03b1 up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J. Immunol. 180, 7368\u20137375 (2008).","DOI":"10.4049\/jimmunol.180.11.7368"},{"key":"1643_CR64","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","volume":"177","author":"K Ritis","year":"2006","unstructured":"Ritis, K. et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794\u20134802 (2006).","journal-title":"J. Immunol."},{"key":"1643_CR65","doi-asserted-by":"publisher","first-page":"103378","DOI":"10.1016\/j.ebiom.2021.103378","volume":"67","author":"S de Bruin","year":"2021","unstructured":"de Bruin, S. et al. Clinical features and prognostic factors in COVID-19: a prospective cohort study. EBioMedicine 67, 103378 (2021).","journal-title":"EBioMedicine"},{"key":"1643_CR66","doi-asserted-by":"publisher","unstructured":"Vlaar, A. P. J. et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(20)30341-6 (2020).","DOI":"10.1016\/S2665-9913(20)30341-6"},{"key":"1643_CR67","doi-asserted-by":"crossref","unstructured":"Cinatl, J. et al. Treatment of SARS with human interferons. Lancet 362, 293\u2013294 (2003).","DOI":"10.1016\/S0140-6736(03)13973-6"},{"key":"1643_CR68","unstructured":"Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, e764\u2013e773 (2021)."},{"key":"1643_CR69","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IFN Hung","year":"2020","unstructured":"Hung, I. F. N. et al. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695\u20131704 (2020).","journal-title":"Lancet"},{"key":"1643_CR70","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"Pan, H. et al. Repurposed antiviral drugs for COVID-19 \u2014 interim WHO Solidarity Trial results. N. Engl. J. Med. 384, 497\u2013511 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR71","doi-asserted-by":"crossref","unstructured":"van Laarhoven, A. et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Med (N Y.) 2, 1163\u20131170 (2021).","DOI":"10.1016\/j.medj.2021.09.003"},{"key":"1643_CR72","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00134-021-06377-3","volume":"47","author":"LS Nguyen","year":"2021","unstructured":"Nguyen, L. S., Ait Hamou, Z., Gastli, N., Chapuis, N. & P\u00e8ne, F. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. Intensive Care Med. 47, 619\u2013621 (2021).","journal-title":"Intensive Care Med."},{"key":"1643_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1001\/jamanetworkopen.2020.16485","volume":"3","author":"PF Laterre","year":"2020","unstructured":"Laterre, P. F. et al. Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19). JAMA Netw. Open 3, 3\u20137 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1643_CR74","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/rth2.12349","volume":"4","author":"JJ Shatzel","year":"2020","unstructured":"Shatzel, J. J. et al. The contact activation system as a potential therapeutic target in patients with COVID\u201019. Res. Pract. Thromb. Haemost. 4, 500\u2013505 (2020).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"1643_CR75","doi-asserted-by":"publisher","first-page":"57555","DOI":"10.7554\/eLife.57555","volume":"9","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk, F. L. et al. Kallikrein\u2013kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife 9, 57555 (2020).","journal-title":"eLife"},{"key":"1643_CR76","doi-asserted-by":"publisher","first-page":"e2017708","DOI":"10.1001\/jamanetworkopen.2020.17708","volume":"3","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk, F. L. et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw. Open 3, e2017708 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1643_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-021-05027-9","volume":"22","author":"E Mansour","year":"2021","unstructured":"Mansour, E. et al. Evaluation of the efficacy and safety of icatibant and C1 esterase\/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials 22, 1\u201313 (2021).","journal-title":"Trials"},{"key":"1643_CR78","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319\u2013329 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1643_CR79","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.jacc.2021.02.035","volume":"77","author":"AH Talasaz","year":"2021","unstructured":"Talasaz, A. H. et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19. J. Am. Coll. Cardiol. 77, 1903\u20131921 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1643_CR80","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.thromres.2020.12.024","volume":"199","author":"N Mu\u00f1oz-Rivas","year":"2021","unstructured":"Mu\u00f1oz-Rivas, N. et al. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: a retrospective study. Thromb. Res. 199, 132\u2013142 (2021).","journal-title":"Thromb. Res."},{"key":"1643_CR81","unstructured":"Mazloomzadeh, S. et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit. JAMA 325, 1620\u20131630 (2021)."},{"key":"1643_CR82","doi-asserted-by":"crossref","unstructured":"Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253\u20132263 (2021).","DOI":"10.1016\/S0140-6736(21)01203-4"},{"key":"1643_CR83","doi-asserted-by":"crossref","unstructured":"ATTACC Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N. Engl. J. Med. 385, 790\u2013802 (2021).","DOI":"10.1056\/NEJMoa2105911"},{"key":"1643_CR84","doi-asserted-by":"crossref","unstructured":"REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N. Engl. J. Med. 385, 777\u2013789 (2021).","DOI":"10.1056\/NEJMoa2103417"},{"key":"1643_CR85","doi-asserted-by":"crossref","unstructured":"Bendib, I. et al. Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS. Crit. Care 25, 23 (2021).","DOI":"10.1186\/s13054-020-03427-y"},{"key":"1643_CR86","doi-asserted-by":"crossref","unstructured":"Richeldi, L. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365, 1079\u20131087 (2011).","DOI":"10.1056\/NEJMoa1103690"},{"key":"1643_CR87","doi-asserted-by":"crossref","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm. Med. 20, 3 (2020).","DOI":"10.1186\/s12890-019-1030-4"},{"key":"1643_CR88","doi-asserted-by":"crossref","unstructured":"Menshawey, R., Menshawey, E., Alserr, A. H. K. & Abdelmassih, A. F. JAK out of the box; the rationale behind Janus kinase inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. Cardiovasc. Endocrinol. Metab. 10, 80\u201388 (2021).","DOI":"10.1097\/XCE.0000000000000237"},{"key":"1643_CR89","doi-asserted-by":"crossref","unstructured":"Henderson, L. A. et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV\u20102 and hyperinflammation in pediatric COVID\u201019: version 1. Arthritis Rheumatol. 72, 1791\u20131805 (2020).","DOI":"10.1002\/art.41454"},{"key":"1643_CR90","doi-asserted-by":"crossref","unstructured":"Pouletty, M. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann. Rheum. Dis. 79, 999\u20131006 (2020).","DOI":"10.1136\/annrheumdis-2020-217960"},{"key":"1643_CR91","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein, L. R. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 383, 334\u2013346 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR92","doi-asserted-by":"crossref","unstructured":"Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. Brit. Med. J. 369, m2094 (2020).","DOI":"10.1136\/bmj.m2094"},{"key":"1643_CR93","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/jama.2020.10374","volume":"324","author":"EW Cheung","year":"2020","unstructured":"Cheung, E. W. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 324, 294 (2020).","journal-title":"JAMA"},{"key":"1643_CR94","doi-asserted-by":"crossref","unstructured":"Ramcharan, T. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr. Cardiol. 41, 1391\u20131401 (2020).","DOI":"10.1007\/s00246-020-02391-2"},{"key":"1643_CR95","doi-asserted-by":"crossref","unstructured":"Nakra, N., Blumberg, D., Herrera-Guerra, A. & Lakshminrusimha, S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children 7, 69 (2020).","DOI":"10.3390\/children7070069"},{"key":"1643_CR96","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1172\/JCI141113","volume":"130","author":"PY Lee","year":"2020","unstructured":"Lee, P. Y. et al. Distinct clinical and immunological features of SARS-CoV-2\u2013induced multisystem inflammatory syndrome in children. J. Clin. Invest. 130, 5942\u20135950 (2020).","journal-title":"J. Clin. Invest."},{"key":"1643_CR97","doi-asserted-by":"crossref","unstructured":"Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259\u2013269 (2020).","DOI":"10.1001\/jama.2020.10369"},{"key":"1643_CR98","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.26224","volume":"93","author":"M Riollano\u2010Cruz","year":"2021","unstructured":"Riollano\u2010Cruz, M. et al. Multisystem inflammatory syndrome in children related to COVID\u201019: A New York City experience. J. Med. Virol. 93, 424\u2013433 (2021).","journal-title":"J. Med. Virol."},{"key":"1643_CR99","doi-asserted-by":"crossref","unstructured":"Ruscitti, P. et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front. Immunol. 11, 1130 (2020).","DOI":"10.3389\/fimmu.2020.01130"},{"key":"1643_CR100","doi-asserted-by":"crossref","unstructured":"Morris, S. B. et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection \u2014 United Kingdom and United States, March\u2013August 2020. MMWR. Morb. Mortal. Wkly. Rep. 69, 1450\u20131456 (2020).","DOI":"10.15585\/mmwr.mm6940e1"},{"key":"1643_CR101","doi-asserted-by":"crossref","unstructured":"Bastug, A. et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Rheumatol. Int. 41, 993\u20131008 (2021).","DOI":"10.1007\/s00296-021-04843-1"},{"key":"1643_CR102","doi-asserted-by":"crossref","unstructured":"Uwaydah, A. K., Hassan, N. M. M., Abu Ghoush, M. S. & Shahin, K. M. M. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Rep. 14, e242060 (2021).","DOI":"10.1136\/bcr-2021-242060"},{"key":"1643_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2102605","volume":"385","author":"MBF Son","year":"2021","unstructured":"Son, M. B. F. et al. Multisystem inflammatory syndrome in children \u2014 initial therapy and outcomes. N. Engl. J. Med. 385, 11\u201322 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR104","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2102968","volume":"385","author":"AJ McArdle","year":"2021","unstructured":"McArdle, A. J. et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 385, 11\u201322 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR105","doi-asserted-by":"crossref","unstructured":"Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855\u2013864 (2021).","DOI":"10.1001\/jama.2021.0694"},{"key":"1643_CR106","doi-asserted-by":"crossref","unstructured":"D\u00f6cke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-\u03b3 treatment. Nat. Med. 3, 678\u2013681 (1997).","DOI":"10.1038\/nm0697-678"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01643-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01643-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01643-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T06:25:36Z","timestamp":1666679136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01643-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01643-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}